Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study
Nina Boje Kibsgaard Jensen(Aarhus University Hospital), Kari Tanderup(Aarhus University), Peter Hoskin(University of Manchester), Ina M. Jürgenliemk‐Schulz(University Medical Center Utrecht), Jacob Christian Lindegaard(Aarhus University Hospital), Kathrin Kirchheiner(Comprehensive Cancer Center Vienna), R. Mazeron(Centre Léon Bérard), Barbara Šegedin(Institute of Oncology Ljubljana), Christian Kirisits(Comprehensive Cancer Center Vienna), Richard Pötter(Medical University of Vienna), Lars Fokdal(Aarhus University Hospital), Umesh Mahantshetty(Homi Bhabha National Institute)
Cited by 94
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology
|Radiotherapy and Oncology|2006|1.6k
Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group☆ (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV
|Radiotherapy and Oncology|2005|1.5k
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
|Clinical and Translational Radiation Oncology|2018|932